Tier 1 — highest
Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial
PLOS ONE
2016
11(11):e0163716
Bibliography
- PubMed
- PMID 27832073
- PubMed Central
- PMC5104323
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
- Funding
- Funded by NIH/NHLBI grant U01HL105569. The publication states that the sponsor had no role in study design, data collection, analysis, interpretation or manuscript writing.
- Competing interests
- The publication reports outside grants and personal fees for Robert A Wise from multiple pharmaceutical companies; see the paper for full disclosures.
Study snapshot
| Design | Three-arm parallel randomized double-blind placebo-controlled Phase II trial |
|---|---|
| Model | Adults meeting GOLD criteria for COPD |
| Sample | 89 participants |
| Intervention | Placebo, 25 µmol sulforaphane daily, or 150 µmol sulforaphane daily. |
| Duration | 4 weeks |
| Endpoints | Nrf2 target-gene expression in alveolar macrophages; Nrf2 target-gene expression in bronchial epithelial cells; Oxidative stress markers; Airway inflammation; Pulmonary function |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Sulforaphane Detoxification: What Human Pollution & Smoker Trials ShowDoes sulforaphane detox the body? Human trials show increased excretion of selected benzene, acrolein and tobacco-smoke metabolites—but not a generic cleanse or...Read analysis
- Sulforaphane & NRF2: What Human Trials Actually ShowSulforaphane and NRF2 explained from mechanism to humans: KEAP1 signaling, positive airway gene-expression data, the null COPD trial, bioavailability and why pathway...Read analysis
- Sulforaphane Dosage: Human Trial Doses, µmol to mg & MyrosinaseSulforaphane dosage explained without label confusion: human trial doses, µmol-to-mg conversion, glucoraphanin vs sulforaphane, myrosinase, bioavailability and safety.Read analysis
- Sulforaphane Benefits: Human Evidence Ranked by Strength (2026)Sulforaphane benefits ranked by human evidence across 37 papers: bioavailability, pollutant biomarkers, blood sugar, autism, NRF2, H. pylori, cancer and key limitations.Read analysis
- Sulforaphane Supplement Guide: Forms, Myrosinase & Human EvidenceThe evidence-led sulforaphane supplement pillar: forms, active myrosinase, delivered dose, bioavailability, benefits, dosage, safety, foods and the complete 37-paper evidence architecture.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
